Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target
02:19 AM EDT, 05/21/2024 (MT Newswires) -- Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target Price (AUD): $0.28, Change: $, Percent Change: -1.75%
Euroz Hartleys Adjusts Botanix Pharmaceutical's Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy
03:24 AM EDT, 05/13/2024 (MT Newswires) -- Euroz Hartleys Adjusts Botanix Pharmaceutical's Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy Price (AUD): $0.28, Change: $+0.01, Percent C
Botanix Pharmaceuticals Price Target Raised 10% to A$0.33/Share by Euroz Hartleys
Botanix Pharmaceuticals Price Target Raised 10% to A$0.33/Share by Euroz Hartleys
We're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Botanix Pharmaceuticals Price Target Raised 12% to A$0.19/Share by Petra Capital
Botanix Pharmaceuticals Price Target Raised 12% to A$0.19/Share by Petra Capital
If You'd Put $40,000 in This ASX Healthcare Stock at the Start of 2023, You'd Have $128,000 Now
You may have missed the boat, but checking out ASX shares that have exploded is still a fun activity.
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication
The US Food and Drug Administration accepted the resubmission of a new drug application for Botanix Pharmaceuticals' (ASX:BOT) Sofdra-branded topical medication sofpironium bromide gel, 15%. The resub
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%
Botanix Pharmaceuticals (ASX:BOT) completed its new drug application resubmission to the US Food and Drug Administration for its Sofdra-branded topical medication sofpironium bromide gel, 15%. The der
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%
Botanix Pharmaceuticals (ASX:BOT) completed a human factor validation study that evaluated the revised instruction for use of the Sofdra-branded topical medication sofpironium bromide gel, 15%, accord
Botanix Pharmaceuticals Initiated at Hold by Petra Capital
Botanix Pharmaceuticals Initiated at Hold by Petra Capital
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication
Botanix Pharmaceuticals (ASX:BOT) secured feedback from the US Food and Drug Administration related to the planned new drug application resubmission for its Sofdra-branded topical medication sofpironi
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement
Dermatology company Botanix Pharmaceuticals (ASX:BOT) on Friday issued 103,846,155 ordinary shares at AU$0.13 apiece under an institutional placement to raise AU$13.5 million. Proceeds will be used to
Botanix Pharmaceuticals Price Target Cut 3.2% to A$0.30/Share by Euroz Hartleys
Botanix Pharmaceuticals Price Target Cut 3.2% to A$0.30/Share by Euroz Hartleys
Botanix Pharmaceuticals to Raise AU$13.5 Million in Placement; Shares Fall 3%
Botanix Pharmaceuticals (ASX:BOT) is set to raise aU$13.5 million via the placing of 103,846,154 shares at AU$0.13 apiece, the dermatology firm said on Monday. Proceeds will be used to support the upc
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product
Botanix Pharmaceuticals (ASX:BOT) signed an exclusive deal with telehealth firm UpScriptHealth to support the future launch of the Sofdra (sofpironium bromide) gel 15% for the treatment of primary axi
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name
Botanix Pharmaceuticals (ASX:BOT) secured conditional clearance from the US Food and Drug Administration for the use of the 'Sofdra' trade name for its sofpironium bromide medication. The approval is
Botanix Pharmaceuticals (ASX:BOT) Shareholders Have Earned a 138% Return Over the Last Year
Botanix Pharmaceuticals Target Price Cut 6.1% to A$0.31/Share by Euroz Hartleys>BOT.AU
Botanix Pharmaceuticals Target Price Cut 6.1% to A$0.31/Share by Euroz Hartleys>BOT.AU
Botanix Pharmaceuticals (ASX:BOT) Suffers Setback in FDA Approval for Sofpironium Bromide Gel to Treat Hyperhidrosis
Botanix Pharmaceuticals Promotes COO to CEO
Botanix Pharmaceuticals Ltd (ASX:BOT) appointed Howie McKibbon as chief executive, effective Thursday. McKibbon previously served as the company's chief operating officer, according to a Friday news r
No Data